Download PDFPDF

1349 TROCEPT mediated in-tumor delivery of immune checkpoint inhibitors reduces systemic toxicity risks and boosts immune activation
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address